• Walter O Vasquez-Bonilla, Roberto Orozco, Víctor Argueta, Manuel Sierra, Lysien I Zambrano, Fausto Muñoz-Lara, Dennis Salomón López-Molina, Kovy Arteaga-Livias, Zachary Grimes, Clare Bryce, Alberto Paniz-Mondolfi, and Alfonso J Rodríguez-Morales.
• Department of Pathology, Hospital General San Juan de Dios, Guatemala City (Ciudad de Guatemala), 01001, Guatemala; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), Pereira, Risaralda, 660003, Colombia.
• Hum. Pathol. 2020 Nov 1; 105: 74-83.

AbstractCoronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has been declared by the World Health Organization as an emerging public health problem of global importance and classified as a pandemic. SARS-CoV-2 infection can result in diverse, multiorgan pathology, the most significant being in the lungs (diffuse alveolar damage in its different phases, microthrombi, bronchopneumonia, necrotizing bronchiolitis, viral pneumonia), heart (lymphocytic myocarditis), kidney (acute tubular injury), central nervous system (microthrombi, ischemic necrosis, acute hemorrhagic infarction, congestion, and vascular edema), lymph nodes (hemophagocytosis and histiocytosis), bone marrow (hemophagocytosis), and vasculature (deep vein thrombosis). An understanding of the spectrum and frequency of histologic findings in COVID-19 is essential for gaining a better understanding of disease pathophysiology and its ongoing impact on public health. To this end, we conducted a systematic meta-analysis of histopathologic observations to date and review the reported findings.Copyright © 2020 Elsevier Inc. All rights reserved.

29 keywords...

hide…